Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability

John H Strickler; Herbert I Hurwitz

doi:10.1634/theoncologist.2011-0358

Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability

Oncologist. 2012;17(1):9-10. doi: 10.1634/theoncologist.2011-0358. Epub 2012 Jan 10.

Authors

John H Strickler¹, Herbert I Hurwitz

Affiliation

¹ Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, North Carolina 27710, USA.

Abstract

Results of a study, published in this issue of The Oncologist, comparing capecitabine and oxaliplatin plus bevacizumab with the same regimen for only six cycles followed by bevacizumab monotherapy in metastatic colorectal cancer patients are examined.

Publication types

Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Colorectal Neoplasms / drug therapy*
Female
Humans
Male

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab